急性脑损伤患者颅内高压的治疗:分级、时机与结局的关联——SYNAPSE-ICU研究数据
SYNAPSE-ICU研究预设亚分析纳入2320例急性脑损伤患者,描述入住ICU第一周内按治疗强度水平(TIL)分级的颅内高压治疗及其与6个月死亡和神经功能结局的关联。未使用基础TIL者占16.5%,轻-中度TIL占70.8%,极端TIL占12.7%。与极端TIL相比,未使用基础TIL者6个月死亡风险升高(HR=1.612,95%CI 1.243-2.091,p<0.001),轻-中度TIL与极端TIL无差异(HR=1.017,95%CI 0.823-1.257,p=0.873);TIL使用与神经功能结局无显著关联。作者认为,在选定患者中积极策略可能对6个月死亡有益,但对神经功能结局无益。
要点
- 入住ICU第一周内,未使用基础TIL者较极端TIL者6个月死亡风险升高(HR=1.612,95%CI 1.243-2.091,p<0.001)。
- 轻-中度TIL与极端TIL相比,6个月死亡风险无差异(HR=1.017,95%CI 0.823-1.257,p=0.873)。
- TIL使用与6个月神经功能结局无显著关联。
- 接受极端TIL者更年轻(中位49岁 vs 56岁,p<0.001)、伤前心血管合并症更少(31.4% vs 44%,p<0.001)、神经功能恶化更多(56.1% vs 33.3%,p<0.001)、ICP监测更频繁(74.9% vs 51.2%,p<0.001)。
- 各中心和各国之间极端TIL的使用频率和类型存在相当大的差异。
适用人群与场景
- 急性脑损伤(ABI)成人患者,入住ICU第一周内。
- 中位年龄55岁(I-III四分位数39-69岁),女性800例(34.5%)。
处置流程与药物剂量
- 颅内高压治疗按治疗强度水平(TIL)分级:无基础TIL、轻-中度TIL、极端TIL(eTIL)。
- 入住ICU第一周内,无基础TIL用于382例(16.5%),轻-中度TIL用于1643例(70.8%),极端TIL用于295例(12.7%)。
红旗征与不能漏的情况
- 神经功能恶化(neuroworsening):极端TIL组160例(56.1%) vs 非极端TIL组653例(33.3%),p<0.001。
研究设计与关键结果
- 研究类型:SYNAPSE-ICU研究的预设亚分析,多中心、前瞻性、国际、观察性队列研究,描述入住ICU第一周内ABI患者的ICP治疗并按TIL分级。
- 样本量:2320例患者纳入分析。
- 主要终点(6个月死亡):与极端TIL相比,无基础TIL者死亡风险升高(HR=1.612,95%CI 1.243-2.091,p<0.001);轻-中度TIL与极端TIL无差异(HR=1.017,95%CI 0.823-1.257,p=0.873)。
- 神经功能结局:TIL使用与神经功能结局无显著关联。
- 极端TIL组特征:更年轻(中位年龄49岁(I-III四分位数35-62岁) vs 56岁(40-69岁),p<0.001);伤前心血管合并症更少(90例(31.4%) vs 859例(44%),p<0.001);神经功能恶化更多(160例(56.1%) vs 653例(33.3%),p<0.001);ICP监测更频繁(221例(74.9%) vs 1037例(51.2%),p<0.001)。
- 各中心和各国之间极端TIL的使用频率和类型存在相当大的差异。
证据类型、等级与局限
- 证据类型:多中心、前瞻性、国际、观察性队列研究的预设亚分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在选定患者中,积极策略(极端TIL)可能对6个月死亡有益,但对神经功能结局无益。
- 各中心和各国之间极端TIL的使用频率和类型存在相当大的差异,提示治疗实践存在变异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Uncertainties remain about the safety and efficacy of therapies for managing intracranial hypertension in acute brain injured (ABI) patients. This study aims to describe the therapeutical approaches used in ABI, with/without intracranial pressure (ICP) monitoring, among different pathologies and across different countries, and their association with six months mortality and neurological outcome.
METHODS: A preplanned subanalysis of the SYNAPSE-ICU study, a multicentre, prospective, international, observational cohort study, describing the ICP treatment, graded according to Therapy Intensity Level (TIL) scale, in patients with ABI during the first week of intensive care unit (ICU) admission.
RESULTS: 2320 patients were included in the analysis. The median age was 55 (I-III quartiles = 39-69) years, and 800 (34.5%) were female. During the first week from ICU admission, no-basic TIL was used in 382 (16.5%) patients, mild-moderate in 1643 (70.8%), and extreme in 295 cases (eTIL, 12.7%). Patients who received eTIL were younger (median age 49 (I-III quartiles = 35-62) vs 56 (40-69) years, p < 0.001), with less cardiovascular pre-injury comorbidities (859 (44%) vs 90 (31.4%), p < 0.001), with more episodes of neuroworsening (160 (56.1%) vs 653 (33.3%), p < 0.001), and were more frequently monitored with an ICP device (221 (74.9%) vs 1037 (51.2%), p < 0.001). Considerable variability in the frequency of use and type of eTIL adopted was observed between centres and countries. At six months, patients who received no-basic TIL had an increased risk of mortality (Hazard ratio, HR = 1.612, 95% Confidence Interval, CI = 1.243-2.091, p < 0.001) compared to patients who received eTIL. No difference was observed when comparing mild-moderate TIL with eTIL (HR = 1.017, 95% CI = 0.823-1.257, p = 0.873). No significant association between the use of TIL and neurological outcome was observed.
CONCLUSIONS: During the first week of ICU admission, therapies to control high ICP are frequently used, especially mild-moderate TIL. In selected patients, the use of aggressive strategies can have a beneficial effect on six months mortality but not on neurological outcome.
参考来源
- Robba C, Graziano F, Guglielmi A, et al. Treatments for intracranial hypertension in acute brain-injured patients: grading, timing, and association with outcome. Data from the SYNAPSE-ICU study. Intensive Care Med. 2023. PMID: 36622462. doi:10.1007/s00134-022-06937-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。